Becoming A Clinical-Stage Biotech

By Dan Schell, Chief Editor, Clinical Leader

Our October 2019 issue featured Laura Indolfi , CEO and cofounder of PanTher Therapeutics, in an article titled “Program Winners Look Back On Year Of Change.” Her company, which makes minimally invasive implantable devices that deliver direct, localized, and sustained cancer therapy to solid tumors, had won the first Massachusetts Next Generation Initiative (MassNext-Gen), a competitive program to support women entrepreneurs in early-stage life sciences companies. In June of this year, PanTher closed an oversubscribed $5.4M Series A, which sets the stage for the company’s first clinical trial. We asked her to share some of her learnings from this key milestone and from the company’s recent decision to expand its board.